^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mucosal Melanoma |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
Published date:
01/24/2021
Excerpt:
Junshi Biosciences...announced today that U.S. Food and Drug Administration (FDA) has granted toripalimab Fast Track designation for the first-line treatment of mucosal melanoma.
